Huber K - Search Results

1

Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.

Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, Jilma B. Siller-Matula JM, et al. Among authors: huber k. J Thromb Haemost. 2012 Apr;10(4):529-42. doi: 10.1111/j.1538-7836.2012.04639.x. J Thromb Haemost. 2012. PMID: 22260716 Free article.

2

Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay.

Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B. Siller-Matula JM, et al. Among authors: huber k. J Thromb Haemost. 2010 Feb;8(2):351-9. doi: 10.1111/j.1538-7836.2009.03699.x. Epub 2009 Nov 23. J Thromb Haemost. 2010. PMID: 19943879 Free article.

3

Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis.

Siller-Matula JM, Jilma B, Schrör K, Christ G, Huber K. Siller-Matula JM, et al. Among authors: huber k. J Thromb Haemost. 2010 Dec;8(12):2624-41. doi: 10.1111/j.1538-7836.2010.04049.x. J Thromb Haemost. 2010. PMID: 20831618 Free article. Review.

4

A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis.

Huber K, Jörg M, Probst P, Schuster E, Lang I, Kaindl F, Binder BR. Huber K, et al. Thromb Haemost. 1992 Feb 3;67(2):209-13. Thromb Haemost. 1992. PMID: 1621240

5

Thrombolytic therapy in acute myocardial infarction.

Huber K, Maurer G. Huber K, et al. Semin Thromb Hemost. 1996;22(1):15-26. doi: 10.1055/s-2007-998988. Semin Thromb Hemost. 1996. PMID: 8711486 Review.

6

Plasma Lp(a) levels are increased in patients with chronic thromboembolic pulmonary hypertension.

Ignatescu M, Kostner K, Zorn G, Kneussl M, Maurer G, Lang IM, Huber K. Ignatescu M, et al. Among authors: huber k. Thromb Haemost. 1998 Aug;80(2):231-2. Thromb Haemost. 1998. PMID: 9716143 Clinical Trial.

7

Predictive value of PAI-1 plasma activity and thallium perfusion imaging for restenosis after percutaneous transluminal angioplasty in clinically asymptomatic patients.

Gottsauner-Wolf M, Sochor H, Hornykewycz S, Beckmann R, Lang I, Probst P, Binder BR, Huber K. Gottsauner-Wolf M, et al. Among authors: huber k. Thromb Haemost. 1999 Apr;81(4):522-6. Thromb Haemost. 1999. PMID: 10235432

8

Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents.

Katsaros KM, Speidl WS, Kastl SP, Zorn G, Huber K, Maurer G, Glogar D, Wojta J, Christ G. Katsaros KM, et al. Among authors: huber k. J Thromb Haemost. 2008 Mar;6(3):508-13. doi: 10.1111/j.1538-7836.2007.02884.x. Epub 2007 Dec 25. J Thromb Haemost. 2008. PMID: 18182031 Free article.

9

Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points.

Siller-Matula JM, Tentzeris I, Vogel B, Schacherl S, Jarai R, Geppert A, Unger G, Huber K. Siller-Matula JM, et al. Among authors: huber k. Clin Res Cardiol. 2010 Oct;99(10):645-50. doi: 10.1007/s00392-010-0165-3. Epub 2010 Apr 20. Clin Res Cardiol. 2010. PMID: 20405134

10

High soluble Fas and soluble Fas Ligand serum levels before stent implantation are protective against restenosis.

Katsaros KM, Wiesbauer F, Speidl WS, Kastl SP, Huber K, Zorn G, Niessner A, Glogar D, Maurer G, Wojta J. Katsaros KM, et al. Among authors: huber k. Thromb Haemost. 2011 May;105(5):883-91. doi: 10.1160/TH10-09-0566. Epub 2011 Feb 28. Thromb Haemost. 2011. PMID: 21359408

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,097 results

Search Page

Filters